Keywords: Cyps; cyclophilins; CypA; cyclophilin A; PPIases; peptidyl-prolyl isomerases; CsA; cyclosporin A; HIV-1; human immunodeficiency virus 1; HCV; hepatitis C virus; SBDD; structure-based drug design; FBDD; fragment-based drug discovery; MD; molecular dynami
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: BBB; blood-brain barrier; CNS; central nervous system; HAT; human African trypanosomiasis; NTDs; neglected tropical diseases; PDB; Protein Data Bank; PPPs; public-private partnerships; R&D; research and development; RNAi; RNA interference; SBDD; structure
Keywords: PAN; polymerase acidic protein N-terminal domain; MD; molecular dynamics; MM/GBSA; molecular mechanics/generalized Born surface area; H5N1; hemagglutinin type 5 and neuraminidase type; M2 protein; matrix protein 2; HIV; human immunodeficiency virus; SBDD;
Discovery of orally efficacious RORγt inverse agonists. Part 2: Design, synthesis, and biological evaluation of novel tetrahydroisoquinoline derivatives
Keywords: RORγt; retinoic acid receptor-related orphan receptor-gamma t; EAE; experimental autoimmune encephalomyelitis; BODIPY; boron-dipyrromethene; TR-FRET; time-resolved fluorescence resonance energy transfer; SAR; structure-activity relationship; IFN-γ; inte
Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations
Keywords: Huntington's disease; Histone deacetylases; Inhibitors of HDAC4; Computer-assisted drug design; QM/MM approach; B3LYP; hybrid gradient-corrected exchange-correlation functional of electron density; CADD; computer-assisted drug design; DCHA; trans-(2R,3R)-
Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential
Keywords: ADME; absorption, distribution, metabolism, and excretion; AML; acute myelogenous leukemia; AUC; area under the blood concentration time curve; b.i.d.; twice a day; CDK; Cyclin-dependent kinase; CLtotal; clearance; Cmax; maximum drug concentration; CRC; c
Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate
Keywords: Axl; Mer; Structure design; Oncology design; Modeling; Crystallography; SBDD;
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 2
Keywords: Methionine aminopeptidase-2; MetAP2; Metalloprotease; Fragment-based drug discovery; FBDD; Structure-based drug design; SBDD; Pyrazolo[4,3-b]indoles;
Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitors
Keywords: Alk5; Inhibitors; Activin; Kinase; Transforming; Growth; Factor; SBDD;
Recent progress on third generation covalent EGFR inhibitors
Keywords: EGFR; Covalent inhibitor; T790M; Oncogenic mutation; Lung cancer; NSCLC; SBDD; Drug resistance;
Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents
Keywords: PI3K; Cancer; SBDD; Molecular planarity; Solubility; Pharmacokinetic profile
Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD)
Keywords: TAK1; SBDD; Inhibitor; Kinase selectivity
Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors
Keywords: GSK-3; CDK-2; Molecular docking; Molecular dynamics; SBDD; ICKPGBPIOPGQTC-UITAMQMPSA-N; KFVQEAUDWUKSMG-BOPFTXTBSA-N; NSRQEPDSABSJEH-YWEYNIOJSA-N; CLAFIVNSSVOTSP-GDNBJRDFSA-N; AKAOIQHIQLGIQQ-BOPFTXTBSA-N; QMZMFQSCRVRMSU-YWEYNIOJSA-N; SQIZTXJHAKRNIQ-WJDWOHS
Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket
Keywords: Phosphodiesterase 10A; PDE10A; Inhibitors; Schizophrenia; SBDD;
Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors
Keywords: MEK; Bicyclic; Fused-pyridine; Cancer; SBDD;
Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors
Keywords: SBDD; ITK; Indazole; X-ray crystallography; Ï-stacking;
Structure-based design of novel human Pin1 inhibitors (III): Optimizing affinity beyond the phosphate recognition pocket
Keywords: Pin1; Peptidyl-prolyl isomerase; PPIase; Phospho-protein epitope; Anti-cancer; Anti-tumor; Mitosis; SBDD; Structural based drug design; Medicinal chemistry; Cell permeability;
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series
Keywords: SBDD; Kinase inhibitor; PI3K/mTOR dual inhibitor; Cancer; Antitumor; Effective polar surface area; ePSA; Metabolite;
The development of CNS-active LRRK2 inhibitors using property-directed optimisation
Keywords: PD; Parkinson's disease; LRRK2; leucine-rich repeat kinase 2; DLP1; dynamin-like protein 1; FOXO1; forkhead box transcription factor; 4E-BP; eukaryotic initiation factor 4E (eIF4E)-binding protein; SBDD; structure-based drug design; HTS; high throughput
Lead optimization of a dihydropyrrolopyrimidine inhibitor against phosphoinositide 3-kinase (PI3K) to improve the phenol glucuronic acid conjugation
Keywords: WZVLQVVHYKFKAZ-UHFFFAOYSA-NPI3K; Cancer; SBDD; Bioisostere; Glucuronic acid conjugation
Molecular interaction of the first 3 enzymes of the de novo pyrimidine biosynthetic pathway of Trypanosoma cruzi
Keywords: CPSII; carbamoyl-phosphate synthetase II; ATC; aspartate transcarbamoylase; DHO; dihydroorotase; CAD; CPSII-DHO-ATC fusion enzyme; UMP; uridine 5â²-monophosphate; SBDD; structure-based drug design; De novo pyrimidine biosynthetic pathway; Carbamoyl-phosp
A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: Design and synthesis of benzylpyrazole acylsulfonamides
Keywords: PPARγ agonist; Diabetes mellitus; SBDD; Acylsulfonamide; Isosteric replacement;
Structure–activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists
Keywords: PPARγ agonists; Diabetes mellitus; SBDD; Acylsulfonamide; Isosteric replacement
Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
Keywords: MEK; Kinase; SBDD; Allosteric; Pyridopyrimidinedione; Oncology
Structure-based lead identification of ATP-competitive MK2 inhibitors
Keywords: MAPKAPK2; MK2; Anti-TNFα; SBDD; Rheumatoid arthritis
Structure based design of heat shock protein 90 inhibitors acting as anticancer agents
Keywords: HSP90; SBDD; Virtual screening; Anticancer agents;
Structure based evolution of a novel series of positive modulators of the AMPA receptor
Keywords: AMPA receptor; Allosteric modulator; SBDD; Indane; Scaffold hopping
A novel series of positive modulators of the AMPA receptor: Discovery and structure based hit-to-lead studies
Keywords: AMPA receptor; Allosteric modulator; SBDD; Hit-to-lead
A novel series of positive modulators of the AMPA receptor: Structure-based lead optimization
Keywords: AMPA receptor; Positive allosteric modulators; Ion channels; SBDD
Structure-based design of novel human Pin1 inhibitors (II)
Keywords: Pin1; Pin1 inhibitors; Phosphate replacement; PPIase; Anti-cancer agents; SBDD; Carboxylates; Tetrazoles
Design, synthesis, and evaluation of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors
Keywords: PDE-4 inhibitor; SBDD; COPD; Asthma
Structure-guided expansion of kinase fragment libraries driven by support vector machine models
Keywords: FBDD; fragment-based drug design; SBDD; structure-based drug design; QSAR; quantitative structure activity relationship; SVM-FP; support vector machine-fingerprints; PPV; positive predicted value; LE; ligand efficiency; HAC; heavy atom count; AMW; atomi
Structure-based design of novel human Pin1 inhibitors (I)
Keywords: Pin1; PPIase; Anticancer; SBDD; Pin1 inhibitor
Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase
Keywords: Poly(ADP-ribose)polymerase PARP-1; SBDD; X-ray; Quinazolinone; Conformationally restricted
A fluorescence polarization assay for inhibitors of Hsp90
Keywords: Hsp90; Fluorescence polarization; ATPase; SBDD; SAR; Resorcinol; Geldanamycin; 17AAG; Radicicol; PU3
Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling
Keywords: PARP-1; PARP-2; SBDD; X-ray; Homology modelingPARP-1, poly(ADP-ribose)polymerase-1; PARP-2, poly(ADP-ribose) polymerase-2 (PARP-2); NAD+, nicotinamide adenine dinucleotide; PAR, poly(ADP-ribose); SBDD, structure based drug design; NI site, nicotinamide-ri
Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors
Keywords: PARP-1; Poly(ADP-ribose) polymerase-1; PARP-2; Poly(ADP-ribose) polymerase-2 (PARP-2); NAD+; nicotinamide adenine dinucleotide; PAR; Poly(ADP-ribose); NI site; nicotinamide-ribose binding site; AD site; adenine-ribose binding site; Poly(ADP-ribose) polyme